Breaking News Instant updates and real-time market news.

EIDX

Eidos Therapeutics

$26.03

0.12 (0.46%)

, PFE

Pfizer

$41.66

0.28 (0.68%)

08:39
05/07/19
05/07
08:39
05/07/19
08:39

Eidos Therapeutics raised to $51 from $28 at Roth Capital

Roth Capital analyst Yasmeen Rahimi raised her price target for Eidos Therapeutics (EIDX) to $51 from $28 driven by an increase in AG10's annual price from $150,000 to $225,000 and Probability of Success adjustment from 70% to 80% after Pfizer's (PFE) tafamadis received U.S. approval with a high sticker price of $225,000, two months ahead of schedule. The analyst believes this makes life easier for Eidos Therapeutics to maintain and even expedite enrollment into its Phase 3 ATTRibute-CM trial. Rahimi reiterates a Buy rating on Eidos Therapeutics shares.

EIDX

Eidos Therapeutics

$26.03

0.12 (0.46%)

PFE

Pfizer

$41.66

0.28 (0.68%)

  • 10

    May

  • 13

    May

  • 18

    May

  • 31

    May

EIDX Eidos Therapeutics
$26.03

0.12 (0.46%)

02/27/19
JPMS
02/27/19
UPGRADE
JPMS
Overweight
Eidos Therapeutics upgraded to Overweight from Neutral at JPMorgan
02/27/19
JPMS
02/27/19
UPGRADE
Target $39
JPMS
Overweight
JPMorgan says Eidos trial design removes multiple overhangs, ups to Overweight
JPMorgan analyst Anupam Rama upgraded Eidos Therapeutics to Overweight from Neutral, citing his view that the company's design of the ATTRibute-CM study, which incorporates feedback from the FDA, removes multiple overhangs, including the need for a head-to-head study versus tafamidis and a financing overhang. The analyst, who has increased his view of the probability of success for AG10 in the ATTR-CM opportunity, also believes AG10 is likely to generate strategic interest from commercial partners. Rama raised his price target on Eidos shares to $39 from $29.
02/27/19
ROTH
02/27/19
NO CHANGE
Target $28
ROTH
Buy
Eidos addressed stock major overhangs with smart trial design, says Roth Capital
Roth Capital analyst Yasmeen Rahimi believes that Eidos Therapeutics' ATTRibute-CM "smart trial design offers the best of both worlds" with two approvable endpoints, namely a 12-month, placebocontrolled study with primary endpoint of change from baseline in six-minute walk distance, and reduction in all-cause mortality and frequency of CV-related hospitalizations over 30 months. Overall, the analyst thinks the company has addressed the major stock overhangs with this smart design. First, by not waiting for tafamidis approval for a comparator, Eidos Therapeutics' will start its trial six months faster and shorten time to market, and second, it is now "rich in catalysts," Rahimi contends. The analyst reiterates a Buy rating and $28 price target on the shares.
04/17/19
BTIG
04/17/19
INITIATION
BTIG
Buy
Eidos Therapeutics initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated Eidos Therapeutics with a Buy rating and a $38 price target, saying that most of Eidos' stock growth over the next two years is "likely to result from appreciation of the TTR market size... and AG10's attractive properties."
PFE Pfizer
$41.66

0.28 (0.68%)

01/31/19
01/31/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Outperform from Neutral at Credit Suisse and to Buy from Hold at Argus. 2. Tiffany (TIF) upgraded to Overweight from Neutral at Atlantic Equities with analyst Daniela Nedialkova saying the pullback has been largely driven by macro concerns while fundamentals of the brand are strong and preliminary FY19 guidance is conservative. 3. Scotts Miracle-Gro (SMG) upgraded to Neutral from Underweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 4. Geron (GERN) upgraded to Buy from Neutral at B. Riley FBR with analyst George Zavoico saying he believes investors should focus on the pivotal Phase III trial of imetelstat. 5. Ralph Lauren (RL) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Dana Telsey saying the company's improving sakes, combined with ongoing margin expansion, should bolster its earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/20/19
SBSH
02/20/19
UPGRADE
Target $41
SBSH
Neutral
Pfizer resumed with a Neutral from Sell at Citi
Citi analyst Andrew Baum resumed coverage of Pfizer following a period of restriction and upgraded the shares to Neutral from Sell. He also boosted his price target for the shares to $41 from $37. The analyst says the recent pullback in the stock, along with the 5%-8% 2019-2021 consensus estimate reductions, gives him the opportunity to close his Sell rating. He believes management action on business development, cost saving or moves to better monetize Pfizer's Established Product business are likely near-term drivers of the stock.
02/20/19
02/20/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) resumed with a Neutral from Sell at Citi with analyst Andrew Baum saying the recent pullback in the stock, along with the 5%-8% 2019-2021 consensus estimate reductions, gives him the opportunity to close his Sell rating. 2. Transocean (RIG) and Diamond Offshore (DO) were upgraded to Overweight from Underweight at Barclays. 3. American Axle (AXL) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy citing progress with restructuring, GM's (GM) truck cycle, and balance sheet deleveraging. 4. Credit Suisse (CS) upgraded to Hold from Sell at Berenberg. 5. Ipsen (IPSEY) upgraded to Neutral from Sell at Goldman Sachs with analyst Diana Na citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/19
LEHM
02/26/19
NO CHANGE
LEHM
Galapagos weakness could be tied to Pfizer safety alert, says Barclays
Barclays believes the weakness today in Galapagos NV (GLPG) could be attributed to, at least in part, the FDA's safety communication on Pfizer's (PFE) post-marketing study of 10mg daily Xeljanz. Competitor safety issues with higher dose JAK inhibitors was a major focus of Galapagos' post-earnings conference call last week, Barclays tells investors in a research note. Galapagos management, while limited in what it can say pending the data, seems to believe they can get both doses approved, Barclays contends. Further, the firm points out that the company has received no communication and sees no reason to conclude that the FDA has determined that thromboembolic events are a class effect of the JAKs. Shares of Galapagos are down 1.5%, or $1.45, to $97.28 in late morning trading.

TODAY'S FREE FLY STORIES

TILE

Interface

$15.74

-0.28 (-1.75%)

11:10
05/20/19
05/20
11:10
05/20/19
11:10
Conference/Events
Interface management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

GM

General Motors

$36.81

-0.19 (-0.51%)

11:07
05/20/19
05/20
11:07
05/20/19
11:07
Hot Stocks
General Motors unveils new electronic platform »

General Motors announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 04

    Jun

  • 05

    Jun

  • 01

    Aug

DISH

Dish

$31.11

-4.22 (-11.94%)

11:06
05/20/19
05/20
11:06
05/20/19
11:06
Downgrade
Dish rating change  »

Dish downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZVO

Zovio

$4.66

-0.05 (-1.06%)

10:57
05/20/19
05/20
10:57
05/20/19
10:57
Conference/Events
Zovio management to meet with Barrington »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 10

    Jun

  • 11

    Jun

LOW

Lowe's

$108.61

-0.39 (-0.36%)

, HD

Home Depot

$192.49

-0.04 (-0.02%)

10:31
05/20/19
05/20
10:31
05/20/19
10:31
On The Fly
Fly Intel: What to watch in Home Depot, Lowe's earnings reports »

Home improvement…

LOW

Lowe's

$108.61

-0.39 (-0.36%)

HD

Home Depot

$192.49

-0.04 (-0.02%)

AMZN

Amazon.com

$1,851.99

-16.33 (-0.87%)

SHLD

Sears

$0.00

(0.00%)

JCP

J.C. Penney

$1.11

-0.035 (-3.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 24

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 24

    Jun

TSLA

Tesla

$199.00

-12.02 (-5.70%)

, TROW

T. Rowe Price

$103.87

-0.55 (-0.53%)

10:31
05/20/19
05/20
10:31
05/20/19
10:31
On The Fly
Tesla dips below $200 as analysts voice concern over Model 3 demand »

Shares of Tesla (TSLA)…

TSLA

Tesla

$199.00

-12.02 (-5.70%)

TROW

T. Rowe Price

$103.87

-0.55 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

VRNA

Verona Pharma

$5.90

-0.45 (-7.09%)

10:20
05/20/19
05/20
10:20
05/20/19
10:20
Hot Stocks
Verona Pharma presents expanded analysis of ensifentrine clinical data »

Verona Pharma presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$19.26

-0.38 (-1.93%)

, TBPH

Theravance Biopharma

$20.19

-0.44 (-2.13%)

10:19
05/20/19
05/20
10:19
05/20/19
10:19
Hot Stocks
Theravance, Mylan study highlights possible role of Yupelri in COPD treatment »

Theravance Biopharma…

MYL

Mylan

$19.26

-0.38 (-1.93%)

TBPH

Theravance Biopharma

$20.19

-0.44 (-2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

10:19
05/20/19
05/20
10:19
05/20/19
10:19
Conference/Events
Wolfe Research IT hardware analyst to hold an analyst/industry conference call »

IT Hardware &…

GOOS

Canada Goose

$47.69

-0.65 (-1.34%)

, OSW

OneSpaWorld

$13.55

0.05 (0.37%)

10:17
05/20/19
05/20
10:17
05/20/19
10:17
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

GOOS

Canada Goose

$47.69

-0.65 (-1.34%)

OSW

OneSpaWorld

$13.55

0.05 (0.37%)

ZM

Zoom Video

$86.55

-3.36 (-3.74%)

BYND

Beyond Meat

$88.70

-0.63 (-0.71%)

FMC

FMC Corporation

$74.01

-1.24 (-1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 06

    Jun

AAL

American Airlines

$30.38

-1.38 (-4.35%)

, DAL

Delta Air Lines

$54.07

-0.82 (-1.49%)

10:17
05/20/19
05/20
10:17
05/20/19
10:17
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

AAL

American Airlines

$30.38

-1.38 (-4.35%)

DAL

Delta Air Lines

$54.07

-0.82 (-1.49%)

DB

Deutsche Bank

$7.42

-0.16 (-2.11%)

EV

Eaton Vance

$36.91

-0.895 (-2.37%)

PRA

ProAssurance

$38.42

-0.72 (-1.84%)

CLX

Clorox

$147.09

0.03 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 29

    May

  • 03

    Jun

  • 11

    Jun

  • 12

    Jun

  • 12

    Jun

  • 20

    Jun

GD

General Dynamics

$169.82

3.43 (2.06%)

, TGT

Target

$71.62

0.74 (1.04%)

10:17
05/20/19
05/20
10:17
05/20/19
10:17
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

GD

General Dynamics

$169.82

3.43 (2.06%)

TGT

Target

$71.62

0.74 (1.04%)

NPTN

NeoPhotonics

$3.99

0.16 (4.18%)

UAL

United Continental

$81.40

-0.12 (-0.15%)

JACK

Jack in the Box

$82.09

-0.13 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 22

    May

  • 28

    May

  • 29

    May

  • 04

    Jun

  • 12

    Jun

  • 25

    Jun

  • 27

    Jun

  • 08

    Aug

TRN

Trinity Industries

$20.78

-0.15 (-0.72%)

10:17
05/20/19
05/20
10:17
05/20/19
10:17
Hot Stocks
Trinity Industries announces strategic railcar maintenance network expansion »

Trinity Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 13

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
05/20/19
05/20
10:17
05/20/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
05/20/19
05/20
10:16
05/20/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
05/20/19
05/20
10:15
05/20/19
10:15
Conference/Events
Wolfe Research healthcare analyst to hold analyst/industry conference call »

Healthcare Services…

10:15
05/20/19
05/20
10:15
05/20/19
10:15
General news
Oil Action: WTI crude »

Oil Action: WTI crude…

10:15
05/20/19
05/20
10:15
05/20/19
10:15
General news
Fed's Harker didn't discuss policy or the economy »

Fed's Harker…

10:10
05/20/19
05/20
10:10
05/20/19
10:10
General news
U.S. corporate bond update: several issues are on the docket »

U.S. corporate bond…

FLIC

First Long Island

$22.31

(0.00%)

10:04
05/20/19
05/20
10:04
05/20/19
10:04
Hot Stocks
First Long Island names Janet Verneuille EVP, CRO »

The First of Long Island…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSC

Studio City

$17.00

(0.00%)

10:00
05/20/19
05/20
10:00
05/20/19
10:00
Hot Stocks
Studio City falls -7.3% »

Studio City is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNED

Barnes & Noble Education

$3.40

-0.26 (-7.10%)

10:00
05/20/19
05/20
10:00
05/20/19
10:00
Hot Stocks
Barnes & Noble Education falls -7.7% »

Barnes & Noble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEYS

Keysight Technologies

$73.76

-8.12 (-9.92%)

10:00
05/20/19
05/20
10:00
05/20/19
10:00
Hot Stocks
Keysight Technologies falls -9.8% »

Keysight Technologies is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

SMI

SMIC

$5.39

0.38 (7.58%)

10:00
05/20/19
05/20
10:00
05/20/19
10:00
Hot Stocks
SMIC rises 7.6% »

SMIC is up 7.6%, or 38c…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBK

Westpac Banking

$18.98

1.63 (9.39%)

10:00
05/20/19
05/20
10:00
05/20/19
10:00
Hot Stocks
Westpac Banking rises 9.2% »

Westpac Banking is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.